Table 1. Blood-specific mutations in 9 recurrently mutated genes identified in TCGA cases.

Asterisks indicate nonsense mutations. VAF is defined as the proportion of reads supporting the variant allele. 11 cancer types were investigated in this study: BRCA (breast adenocarcinoma), GBM (glioblastoma multiforme), HNSC (head and neck squamous cell carcinoma), KIRC (kidney renal clear cell carcinoma), LGG (brain low grade glioma), LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), OV (ovarian carcinoma), PRAD (prostate adenocarcinoma), STAD (stomach adenocarcinoma), and UCEC (uterine corpus endometrioid carcinoma).

Gene	Mutation	Case			Gene	Mutation	Case
		Type	Age	VAF			Type	Age	VAF
DNMT3A	p.R882C	GBM	81	15.79%	JAK2	p.V617F	GBM	57	21.52%
		STAD	60	18.29%			GBM	72	73.39%
		STAD	69	12.17%			KIRC	59	28.57%
	p.R882H	BRCA	62	21.43%			LGG	45	15.87%
		GBM	64	35.56%			LUAD	72	27.62%
		LUSC	76	31.91%			LUAD	76	41.62%
	e13+1	KIRC	79	15.94%			UCEC	59	35.90%
		LUAD	76	11.11%			UCEC	74	42.92%
	p.E469*	GBM	72	20.60%	ASXL1	p.Q575*	LUAD	75	20%
	p.F851fs	BRCA	64	34.88%		p.Q733*	LUAD	72	14.29%
	p.K577fs	HNSC	72	24.14%		p.Q733fs	UCEC	81	27.27%
	p.N516fs	LUSC	71	33.33%		p.R548fs	LUAD	76	35.03%
	p.S770*	STAD	75	16.03%		p.Y591*	STAD	65	17.88%
	p.W314*	UCEC	74	22.06%		p.Y591fs	LUSC	56	29.70%
	p.Y584fs	GBM	75	38%	TP53	p.C275Y	OV	52	14.29%
	e12–1	PRAD	60	35.79%		p.Q136*	LUAD	null	18%
	e21–2	GBM	76	11.81%		p.Q144*	STAD	62	15.96%
	e22–1	UCEC	77	33.85%		p.R273L	LUAD	70	34.62%
TET2	p.F381fs	GBM	83	50%	GNAS	p.R202H	GBM	76	14.44%
	p.H863fs	GBM	64	11.67%			HNSC	59	11.54%
	p.K889*	OV	85	15.09%			LUAD	69	21.43%
	p.Q531*	KIRC	48	11.90%	PPM1D	p.Q520*	BRCA	79	35.42%
	p.Q644*	UCEC	89	16.78%		p.S468*	UCEC	49	21.23%
	p.Q764fs	GBM	75	33.01%	BCORL1	p.G883E	LUAD	null	16.67%
	p.Q831fs	LUAD	75	26.42%		p.S264*	PRAD	56	22.45%
	p.Q888*	GBM	83	20.39%	SF3B1	p.K700E	GBM	89	13.86%
	p.R550*	LUAD	76	16.25%			KIRC	77	43.04%
	p.T229fs	GBM	72	19.05%